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Hypertrophic cardiomyopathy (HCM) has historically been
regarded as a complex and intellectually challenging cardiac
disease (1–4). However, this disorder has also been a
frequent source of frustration to clinicians and their pa-
tients. The therapeutic uncertainties of HCM are derived
from its diverse pathophysiology and heterogeneous clinical
spectrum (1–4). In addition, the striking morphologic and
functional abnormalities characteristic of the disease, as well
as certain dramatic features of its natural history (such as
sudden death in the absence of prior symptoms), have
conveyed a sense of urgency to develop novel and more
effective treatments.
This complex interplay between investigative interest and
therapeutic necessity has periodically exposed HCM pa-
tients to a broad range of innovative, but particularly bold or
sometimes even questionable, treatment strategies. For ex-
ample, massive doses of beta-adrenergic blocking drugs
(e.g., up to one gram of propranolol per day) have been
administered both to adults and children in an effort to
improve symptoms and prevent disease progression (5). The
argon ion laser has been proposed as an alternative to
conventional surgical techniques for relieving outflow ob-
struction (6). More recently, dual-chamber pacemakers have
been implanted in asymptomatic children without a subaor-
tic gradient and with minimal left ventricular hypertrophy in
an attempt to interfere with the powerful genetic forces that
may lead to the development of outflow obstruction and the
progression of hypertrophy during adolescence (7,8). Ulti-
mately, these strategies have not been incorporated into the
standard therapeutic armamentarium for the disease. The
generally accepted treatment options currently available to
clinicians include drugs (beta-blockers, verapamil and diso-
pyramide) or surgery for the management of congestive
symptoms, and the implantable cardioverter-defibrillator or
amiodarone for those patients judged to be at high risk for
sudden death (9–11).
NEW ALTERNATIVE
THERAPEUTIC OPTIONS TO SURGERY
Currently, ventricular septal myotomy-myectomy (Morrow
operation) represents the gold standard for the management
of patients with a marked outflow gradient under basal
conditions ($50 mm Hg) and severe symptoms of heart
failure refractory to medical therapy (New York Heart
Association functional classes III or IV) (9–11). It should be
emphasized, however, that patients with such clinical fea-
tures represent only a minority of the overall HCM popu-
lation (probably less than 5%) (10,11).
Considerable data assembled over more than 30 years
from a number of centers indicate that about 70% of
patients report substantial and persistent symptomatic im-
provement for five or more years after surgery, and that the
basal outflow gradient is abolished or greatly reduced in
more than 90% of patients (9–16). Because it is not known
whether surgery prolongs survival or reduces the risk of
sudden cardiac death in HCM (3,4,9–11), septal myotomy-
myectomy is only offered to severely limited patients to
improve their quality of life. However, to achieve maximal
benefit with an acceptably low risk (#2% operative mortal-
ity) (9,10,12,16), myotomy-myectomy must be performed
by surgeons with extensive experience with this operation.
Because such expertise is available only at a few centers in
the world, there is ample justification for the development
of therapeutic alternatives to the operation.
Indeed, the recent explosion in cardiovascular technology
and interventional cardiology has in the process also gener-
ated new potential therapeutic options for patients with
HCM. Proposed alternatives to surgery now include dual-
chamber pacing and the induction of localized ventricular
septal infarction by infusion of ethanol into a major septal
perforator branch of the left anterior descending coronary
artery. Although these therapeutic approaches may ulti-
mately prove to have merit, certain important distinctions
should be made between these two very different techniques.
Dual-chamber pacing has now been employed in HCM
for about eight years, but its true efficacy remains uncertain.
Pacing may impair diastolic function (17,18), and the
reduction in the outflow gradient is greatly variable and
generally much more modest than with surgery (19–24).
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Indeed, objective evidence of improved functional capacity
(such as increased exercise time and peak oxygen consump-
tion) have not been convincingly demonstrated with pacing
(19–24). Well-controlled, randomized studies indicate that
the symptomatic improvement during pacing reported in
observational investigations is consistent with a placebo
effect in most patients (22,24,25). These persisting uncer-
tainties regarding the role of dual-chamber pacing in the
treatment of patients with obstructive HCM are also re-
flected in the recent ACC/AHA Guidelines for Implanta-
tion of Pacemakers and Antiarrhythmia Devices. Pacing
was assigned to class IIb for those patients with obstruction
and symptoms refractory to medical therapy, and to class III
for patients with obstruction and symptoms responsive to
drug treatment (26).
Alcohol septal ablation must still be regarded as an
experimental procedure, but it seems to have a more
substantial influence than pacing on the outflow gradient of
patients with HCM (27–30). At present, studies assessing
the efficacy of this technique on symptoms are short-term
and objective evidence of improved exercise capacity is still
limited. The rate of complications, including death, is also
unresolved and seems to differ considerably amongst indi-
vidual practitioners, being closely related to the level of
expertise with the procedure. For example, septal ablation
not uncommonly necessitates permanent pacemaker im-
plantation due to the creation of high-grade atrio-
ventricular block (27,28,30). Also, because the period of
follow up is brief, the long-term safety of septal ablation is
unresolved. This is of concern because it is possible that the
alcohol-induced scars in the ventricular septum could ulti-
mately increase the arrhythmogenicity of a left ventricle
already prone to complex and potentially life-threatening
arrhythmias. This applies particularly to patients undergo-
ing septal ablation relatively early in life who would be
exposed to this risk for a large portion of their life span.
Because of these difficult issues, septal ablation at an
acceptably low risk requires a high level of expertise, which
is available only at those few referral centers that perform a
sufficiently high number of procedures.
Other uncertainties are a natural consequence of the fact
that most specialists in interventional cardiology, despite
their considerable cardiovascular expertise, may not have
extensive experience with HCM. Such a mismatch could
translate into misleading perceptions that newly proposed
therapies (such as septal ablation or pacing) prolong survival
and prevent sudden death and thus represent appropriate
treatment approaches for all HCM patients with an outflow
gradient, including those with no or only mild symptoms.
Therefore, it may be appropriate to re-examine our
understanding of the pathophysiology and clinical course of
HCM in order to draw attention to certain specific issues,
including appropriate patient selection, that could be over-
looked in the enthusiasm for new treatment strategies. As
experience grows, these general considerations can serve as a
platform upon which to establish the most prudent use of
these therapies throughout the broad clinical spectrum of
HCM.
NATURAL HISTORY
Until a few years ago, the literature projected a rather dismal
clinical picture of HCM, in which most patients experi-
enced either progression to incapacitating symptoms of
heart failure or premature and often sudden cardiac death.
More recently, however, we have come to appreciate how
profoundly the overall perception of this disease has been
influenced by biases in patient referral (31,32). Indeed, most
of the published studies on HCM have emanated from a
small number of tertiary institutions focused on the study
and management of this disease (31). Because patients with
severe symptoms, or those at high risk for sudden death,
have been preferentially referred to these centers, the image
of HCM projected in the literature has been based primarily
on the most extreme expressions of the disease spectrum
(31,32).
In recent years, a number of studies have described the
clinical course of HCM in largely unselected patient cohorts
that were more representative of the overall disease spec-
trum (31,33–38). Such studies have shown that many
patients have a favorable clinical course and may achieve
normal life expectancy, often without important symptoms,
and even in the presence of substantial subaortic obstruction
at rest (31,33–38). Indeed, many HCM patients have only
mild symptoms that are usually controlled by medications
and do not, per se, justify aggressive interventions
(10,11,31,33–38). Furthermore, during the last few years,
systematic clinical and genetic screening of HCM pedigrees
has identified many affected but asymptomatic family mem-
bers of all ages who might otherwise have gone undetected
(10,39–42). Therefore, after four decades of intense inves-
tigation, a less pessimistic and more balanced view of HCM
is emerging, in which the disease may often be associated
with little or no disability and a favorable prognosis.
PATHOPHYSIOLOGY
Our understanding of the determinants of clinical course in
HCM has also evolved substantially. The dynamic left
ventricular outflow gradient initially captured the attention
of investigators in the early 1960s and continues to be the
most visible and quantifiable hemodynamic alteration of the
disease. Indeed, before the advent of echocardiography,
clinical identification of HCM was virtually confined to
those patients with a loud heart murmur (associated with
the outflow gradient). Consequently, at that time, the
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obstructive form seemed to represent virtually the entire
clinical spectrum and the subaortic gradient was often
identified with the disease itself (43). We now realize that
most HCM patients have the nonobstructive form (9–11)
and, in many patients, the outflow gradient is compatible
with normal longevity in the absence of significant symp-
toms (10,11,31,33–38).
The present discussion is focused on obstructive HCM
because the new treatment modalities under consideration
here are confined to this hemodynamic form of the disease.
Therefore, it is worth summarizing the significance of the
outflow gradient in HCM as follows. It is not usually
appropriate to intervene with operation (or potential surgi-
cal alternatives) based solely or largely on the presence of a
gradient. On the other hand, when the outflow gradient is
believed to be a major determinant of severe symptoms
unresponsive to medical therapy, then its reduction by such
interventions is justifiable and desirable.
CLINICAL TRIALS IN HCM:
THE IMPORTANCE
OF PROPER PATIENT SELECTION
These evolving views on the natural history and pathophys-
iology of HCM serve as a reference point upon which to
formulate patient selection criteria for trials testing new
treatment strategies. A comparison with coronary artery
disease may help to clarify the unique problems traditionally
associated with establishing consistent and reliable ap-
proaches to the management of HCM. Because ischemic
heart disease is a common and relatively homogeneous
disorder, advances in treatment have been based on the vast
clinical experience accumulated by many clinicians and
investigators throughout the world with a large number of
patients. Conversely, because HCM is an uncommon and
particularly heterogeneous condition, new treatment strate-
gies have often been proposed on the basis of limited
experience derived from small, highly selected patient co-
horts, and subsequently extrapolated to the overall disease
spectrum.
These considerations raise the possibility that some
HCM patients destined to experience a favorable clinical
course will, nevertheless, be exposed to unnecessary inter-
ventions as a consequence of well-intentioned enthusiasm
for innovative therapeutic approaches. For example, in less
than three years, alcohol septal ablation has been performed
in a total of more than 300 HCM patients at two centers in
Germany that have been rapidly accumulating a large
experience with this technique (44–47). In contrast, it has
taken about 20 years to perform a similar number of septal
myotomy-myectomy operations at two major surgical refer-
ral centers for HCM in North America (12,15,16). Such
demographics raise the possibility that the generally ac-
cepted patient selection criteria for surgery, i.e., a marked
outflow gradient under basal conditions and severe symp-
toms (New York Heart Association functional classes III or
IV) refractory to drug treatment (9–16) may have been
softened. Indeed, recent trials evaluating the efficacy of
pacing or septal ablation in HCM have included many
mildly symptomatic patients, as well as patients in whom
subaortic obstruction was not present at rest but was evident
only under provocable conditions (23,27–30), including
some in whom gradients were induced solely with dobut-
amine (30,48). It is well-documented that such dynamic
subaortic gradients can be induced not only in patients with
HCM, but also in normal subjects, using a variety of agents
or maneuvers (including dobutamine) (49,50). Unless cau-
tion is exercised, gradients generated artificially in nonob-
structive patients may be inappropriately used as an indica-
tion for invasive procedures. Indeed, the application of
anything less than strict patient selection criteria and study
designs will make it exceedingly difficult to discern whether
these potential alternatives to surgery are truly effective in
treating patients with HCM.
CONCLUSIONS
Current approaches to developing and testing new treat-
ment strategies for obstructive HCM should be consistent
with the evolution in our understanding of the natural
history and pathophysiology of this challenging disease.
There is now convincing evidence that many patients with
HCM experience a favorable clinical course in the absence
of important disability. Although we do not wish to inhibit
the well-intentioned efforts of many investigators we, nev-
ertheless, believe that a note of caution is warranted regard-
ing new invasive treatment strategies in this disease. Ap-
propriate patient selection is crucial to designing clinical
trials that assess the efficacy of these innovative interven-
tions on the hemodynamics and clinical course of HCM.
Only by enrolling patients with marked outflow obstruction
under basal conditions and severe symptoms refractory to
drug therapy (who would otherwise be regarded as candi-
dates for surgery), will the interests of both clinical investi-
gation and patient care be fully preserved.
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